(MENAFN- GetNews)


"Parkinson's disease psychosis Clinical Trials"DelveInsight's, "Parkinson's disease psychosis - Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Parkinson's disease psychosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight reports that the Parkinson's disease psychosis pipeline includes over five key companies actively developing more than five investigational therapies.

Parkinson's disease psychosis Overview:

Nonmotor symptoms have a major impact on the quality of life of Parkinson's disease (PD) patients and their caregivers, and growing awareness among healthcare professionals highlights their significance. Psychosis is among the most common and debilitating nonmotor symptoms, affecting 20% to 70% of patients in advanced PD stages. It usually emerges in individuals with an intact sensorium during chronic disease progression and is often precipitated or exacerbated by medications. Recent research, however, points to additional risk factors, indicating a multifactorial origin and complex underlying mechanisms. The classification of early- versus late-onset psychosis, both generally and within PD, remains unstandardized, with some studies defining early-onset psychosis as occurring within 2–4 years of PD diagnosis.

Request for a detailed insights report on Parkinson's disease psychosis pipeline insights

"Parkinson's disease psychosis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Parkinson's disease psychosis Therapeutics Market.

Key Takeaways from the Parkinson's disease psychosis Pipeline Report

• DelveInsight's Parkinson's disease psychosis pipeline report highlights an active landscape, with over five companies developing more than five investigational therapies for the treatment of Parkinson's disease psychosis.

• Leading companies in this space, including Vanda Pharmaceuticals, Sumitomo Pharma, and others, are advancing new drugs to enhance the treatment options for this condition. Promising pipeline candidates in various stages of development include Iloperidone, Ulotaront, and additional therapies.

• AbbVie Inc. has been developing tavapadon, a selective D1/D5 receptor partial agonist, for early-stage Parkinson's disease. In December 2025, AbbVie reported positive outcomes from a third Phase 3 trial, showing notable improvements in motor function, and plans to pursue FDA approval later in 2025.

Parkinson's disease psychosis Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Parkinson's disease psychosis Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson's disease psychosis treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Parkinson's disease psychosis market.

Download our free sample page report on Parkinson's disease psychosis pipeline insights

Parkinson's disease psychosis Emerging Drugs

• Iloperidone: Vanda Pharmaceuticals

• Ulotaront: Sumitomo Pharma

Parkinson's disease psychosis Companies

Over five leading companies are actively working on therapies for Parkinson's disease psychosis, with Vanda Pharmaceuticals having a candidate in the most advanced stage, currently in Phase II clinical trials.

DelveInsight's report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Parkinson's disease psychosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Parkinson's disease psychosis Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Parkinson's disease psychosis Therapies and Key Companies: Parkinson's disease psychosis Clinical Trials and advancements

Parkinson's disease psychosis Pipeline Therapeutic Assessment

. Parkinson's disease psychosis Assessment by Product Type

. Parkinson's disease psychosis By Stage

. Parkinson's disease psychosis Assessment by Route of Administration

. Parkinson's disease psychosis Assessment by Molecule Type

Download Parkinson's disease psychosis Sample report to know in detail about the Parkinson's disease psychosis treatment market @ Parkinson's disease psychosis Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Parkinson's disease psychosis Current Treatment Patterns

4. Parkinson's disease psychosis - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Parkinson's disease psychosis Late-Stage Products (Phase-III)

7. Parkinson's disease psychosis Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Parkinson's disease psychosis Discontinued Products

13. Parkinson's disease psychosis Product Profiles

14. Parkinson's disease psychosis Key Companies

15. Parkinson's disease psychosis Key Products

16. Dormant and Discontinued Products

17. Parkinson's disease psychosis Unmet Needs

18. Parkinson's disease psychosis Future Perspectives

19. Parkinson's disease psychosis Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Parkinson's disease psychosis Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

MENAFN21082025003238003268ID1109961374